Collegium Pharmaceutical, Inc.
COLL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,105 | $941 | $949 | $919 |
| - Cash | $150 | $117 | $96 | $71 |
| + Debt | $814 | $829 | $844 | $859 |
| Enterprise Value | $1,769 | $1,652 | $1,697 | $1,708 |
| Revenue | $209 | $188 | $178 | $182 |
| % Growth | 11.4% | 5.8% | -2.3% | – |
| Gross Profit | $129 | $108 | $97 | $98 |
| % Margin | 61.7% | 57.7% | 54.8% | 54% |
| EBITDA | $122 | $94 | $80 | $96 |
| % Margin | 58.1% | 50.1% | 45.3% | 53% |
| Net Income | $32 | $12 | $2 | $13 |
| % Margin | 15% | 6.4% | 1.4% | 6.9% |
| EPS Diluted | 0.84 | 0.34 | 0.074 | 0.35 |
| % Growth | 147.1% | 362% | -79% | – |
| Operating Cash Flow | $78 | $72 | $55 | $85 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | $78 | $72 | $55 | $84 |